Undisclosed second tumor-associated antigen

The 'Undisclosed second tumor-associated antigen' is a placeholder designation used by pharmaceutical companies to protect intellectual property during the early stages of drug development (Genmab Pipeline, 2024). This terminology is most frequently seen in the context of bispecific antibodies, trispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies, where the drug is engineered to bind to two or more distinct targets (Labrijn et al., 2019, Nature Reviews Drug Discovery). The use of a second, often proprietary, antigen is intended to improve the specificity of the treatment for cancer cells over healthy tissues, a concept known as combinatorial targeting (Slaney et al., 2013, Cancer Discovery). By requiring the presence of two antigens for full therapeutic activation, researchers hope to minimize 'on-target, off-tumor' toxicities (Majzner & Mackall, 2018, Cancer Discovery). Furthermore, targeting multiple antigens can help prevent tumor escape, a common issue where cancer cells stop expressing a single target to survive treatment. Because the identity of the antigen is withheld, specific details regarding its molecular structure, physiological function, and expression profile are not publicly available.

Other names

Undisclosed tumor antigenProprietary tumor-associated antigen

Dual-antigen targeting via bispecific or multi-specific antibody formats to enhance tumor selectivity and immune cell engagement.